Programmed death-ligand 1 expression influenced by tissue sample size. Scoring based on tissue microarrays’ and cross-validation with resections, in patients with, stage I–III, non-small cell lung carcinoma of the European Thoracic Oncology Platform Lungscape cohort-Reference-Cited by-同舟云学术

Programmed death-ligand 1 expression influenced by tissue sample size. Scoring based on tissue microarrays’ and cross-validation with resections, in patients with, stage I–III, non-small cell lung carcinoma of the European Thoracic Oncology Platform Lungscape cohort

Published:2019-11-18 Issue:5 Volume:33 Page:792-801
ISSN:0893-3952
Container-title:Modern Pathology
language:en
Short-container-title:Mod Pathol

Author:

Thunnissen Erik, ,Kerr Keith M.,Dafni Urania,Bubendorf Lukas,Finn Stephen P.,Soltermann Alex,Biernat Wojciech^ORCID,Cheney Richard,Verbeken Erik,Warth Arne,Marchetti Antonio,Speel Ernst-Jan M.,Pokharel Saraswati,Quinn Anne Marie,Monkhorst Kim,Navarro Atilio,Madsen Line Bille,Tsourti Zoi,Geiger Thomas,Kammler Roswitha,Peters Solange,Stahel Rolf A.

Publisher

Springer Science and Business Media LLC

Subject

Pathology and Forensic Medicine

Link

http://www.nature.com/articles/s41379-019-0383-9.pdf

Reference27 articles.

1. Melosky B, Chu Q, Juergens R, Leighl N, McLeod D, Hirsh V. Pointed progress in second-line advanced non-small-cell lung cancer: the rapidly evolving field of checkpoint inhibition. J Clin Oncol. 2016;34:1676–88.

2. Assi HI, Kamphorst AO, Moukalled NM, Ramalingam SS. Immune checkpoint inhibitors in advanced non-small cell lung cancer. Cancer. 2018;124:248–61.

3. Gong J, Chehrazi-Raffle A, Reddi S, Salgia R. Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations. J Immunother Cancer. 2018;6:8.

4. Büttner R, Gosney JR, Skov BG, Adam J, Motoi N, Bloom KJ, et al. Programmed death-ligand 1 immunohistochemistry testing: a review of analytical assays and clinical implementation in non-small-cell lung cancer. J Clin Oncol. 2017;35:3867–76.

5. Nakamura S, Hayashi K, Imaoka Y, Kitamura Y, Akazawa Y, Tabata K, et al. Intratumoral heterogeneity of programmed cell death ligand-1 expression is common in lung cancer. PLoS ONE. 2017;12:e0186192.

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Development of Ex Vivo Analysis for Examining Cell Composition, Immunological Landscape, Tumor and Immune Related Markers in Non-Small-Cell Lung Cancer;Cancers;2024-08-20

2. Assessment of RANK/RANK-L prevalence and clinical significance in NSCLC European Thoracic Oncology Platform Lungscape cohort and SPLENDOUR randomized clinical trial;Lung Cancer;2023-01

3. Assessing PD-L1 Expression in Different Tumor Types;Handbook of Cancer and Immunology;2023

4. Prognostic impact of tumour mutational burden in resected stage I and II lung adenocarcinomas from a European Thoracic Oncology Platform Lungscape cohort;Lung Cancer;2022-12

5. Nationwide differences in cytology fixation and processing methods and their impact on interlaboratory variation in PD-L1 positivity;Virchows Archiv;2022-11-12